Preclinical and clinical research

Our preclinical plasma research and development work is carried out at our state-of-the-art site in Vienna, Austria. There, we develop plasma-derived products. We also create new technologies to improve our work and new devices to help patients at home or in hospital. We maintain a strong focus on key regulatory, production, life-cycle management and marketing.

Recombinant R&D involves the development of therapeutic recombinant proteins that resemble the respective proteins in human tissue or blood. This research work is carried out at our Heidelberg site, in Germany.

The molecular biochemistry group in Berlin, Germany, develops technologies to examine the structure and function of plasma-derived and recombinant proteins. It has developed new ways to decode the relationships between different plasma proteins and their influence on the immune system.

All our medicines must help improve the lives of patients and, as part of that, the risk associated with our medicines must be minimised. It is the global virus and prion validation group that does much of the work to ensure this. The group tests and verifies the pathogen inactivation or removal methods used in all Octapharma production processes. The group is located at our facilities in Frankfurt, Germany.

The pharmacology and toxicology department in Vienna, Austria, assesses the tolerability of all new medicines before they are put forward for clinical trials and regulatory approval. It is this department’s responsibility to ensure that the formulation and performance of our medicines are not affected by contact with anything they are stored or distributed in. The department also works with all other departments to manage and enhance product life-cycle management.